Nitric oxide inhalation - AIT

Drug Profile

Nitric oxide inhalation - AIT

Alternative Names: AIT-CF; Nitric oxide inhaled; NOxAST; NOxBR; NOxCF; NOxCureBR; NOxCureCF; NOxPN

Latest Information Update: 10 May 2017

Price : $50

At a glance

  • Originator University of British Columbia
  • Developer AIT; Schneider Childrens Medical Center of Israel; University of British Columbia
  • Class Antiacnes; Antiandrogens; Antibacterials; Antifungals; Antihypertensives; Antivirals; Free radicals; Macromolecular substances; Nitrogen oxides; Non-opioid analgesics; Small molecules; Vasodilators
  • Mechanism of Action Guanylate cyclase stimulants; Reactive oxygen species modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • New Molecular Entity No

Highest Development Phases

  • Phase III Respiratory syncytial virus infections
  • Phase II Chronic obstructive pulmonary disease; Cystic fibrosis; Mycobacterial infections
  • Phase I Respiratory tract infections
  • Discontinued Asthma; Pneumonia

Most Recent Events

  • 24 Apr 2017 Discontinued - Phase-I for Pneumonia in Israel (Inhalation) (AIT pipeline, April 2017)
  • 24 Apr 2017 Discontinued for Asthma in Israel (Inhalation) (AIT pipeline, April 2017)
  • 24 Apr 2017 Phase-II clinical trials in Chronic obstructive pulmonary disease in Israel (Inhalation) (AIT pipeline, April 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top